Thursday, September 25, 2008

3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO

3SBio Inc. , a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has filed with the Chinese State Food and Drug Administration (SFDA) for approval of a 36,000 IU dosage formulation of EPIAO for the treatment of anemia associated with chemotherapy in cancer patients. If approved, high-dose EPIAO would be the only dosage form of this kind available in China.

The details can be read here.

No comments: